Abstract
Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by a blockage in the differentiation of immature hematopoietic cells, leading to the accumulation of myeloid blasts in the bone marrow and impairment of normal hematopoiesis. Despite significant advances in treatments over recent years, therapeutic limitations persist across patient subgroups, highlighting the need …